Our results further support that inhibition of EGFR has effects at least similar to (if not more potent than) inhibition of individual downstream targets and that combinations of EGFR and additional inhibitors of downstream or synergistic pathways (i.e., AZD5438 for CDK2) are more effective than individual inhibitors in protecting against NIHL. This evidence concerns the gene EGFR and noise induced hearing loss.